The Effect of Contingent Value Rights on Drug Approval in Biopharma M&A Open Access
Huddleston, Grant (Spring 2026)
Abstract
Opaque assets in mergers and acquisitions (M&A) create the need for unique transaction structures such as contingent value rights (CVRs) and earnouts. Prior research exposes two main functions of these contingent contracts. The first is to align post acquisitions incentives and retain human capital. The second is to bridge valuation disagreements, allowing inherently riskier assets to sell by spreading uncertainty across parties. The capital-intensive and risk-centric biopharmaceutical industry makes it an ideal setting to explore these functions. This paper aims to address the gap in M&A contracting literature by examining CVRs in biopharmaceutical acquisitions to analyze how contingent payment structures influence drug approval.
This paper compiles 313 biopharma transactions from Evaluate Pharma’s transaction database and assesses their post-acquisition success measure through primary asset approval. The data is comprised of 91 transactions structured with a CVR and 222 with upfront payment. It then models out a linear probability model (LPM), logit, and propensity score model (PSM) to compare the percentage of approved deals. The regression models control for three main determinants of drug approval as found in the literature: inherent drug risk, resource risk, and timing risk. These models produce 13% to 19% lower drug approval in CVR transactions, indicating that contingent contracting in biopharma is primarily used to bridge valuation disagreements and thus is more densely used in transactions with greater underlying risk. While this does not refute the possibility of an incentive aligning hypothesis, the findings provide empirical support that CVRs in biopharma transactions serve to bridge valuation and spread risk for assets with extreme uncertainty.
Table of Contents
Introduction
Introduction to Biopharma Industry
Relevant Literature
Adverse Selection and Asymmetric Information in M&A
The Lemons Problem and Medium of Exchange
Earnouts as Extended Contingent Contracting
Contingent Value Rights: Theory and Mechanisms
CVR Structure and Biopharma Context
The Incentive Alignment Hypothesis
The Adverse Selection and Risk Signaling Hypothesis
Competing Hypotheses
Determinants of Drug Approval Success
Overview of Approval Success Rates
Inherent Drug Risk and Therapeutic Characteristics
Size, Experience, and Capital
Time and Evolution of Regulatory Processes
Research Gap and Synthesis
Theoretical Framework
Construction of Dataset for Empirical Analysis
Transaction Data Collection
Drug Approval Data
CVR Variable Construction
Drug Approval Variable Construction
Control Variables Data
Control Variable Selection
Phase at Deal Close Construction
Therapeutic Area Construction
Log of Deal Size Construction
Age of Deal Construction
Summary Statistics and Initial Observations
Variable Distribution Preliminary
Empirical Assessment and Competing Hypotheses
Empirical Design and Methodology
Linear Probability Model
Logit Model
Propensity Score Matching
Results
Linear Probability Regression
Logit Regression
Propensity Score Matching Results
Covariate Balance
ATT Estimates
Illustrative Case Study
Roche’s acquisition of Trophos: High Common Uncertainty and CVR Usage
Roche’s acquisition of Ignyta: Low Common Uncertainty and Fixed-Price Contract
Hypothesis 2: Theoretical Framework in Context
Conclusion
Appendix
Supplemental Heterogeneity Analysis Tables and Figures
Bibliography
About this Honors Thesis
| School | |
|---|---|
| Department | |
| Degree | |
| Submission | |
| Language |
|
| Research Field | |
| Keyword | |
| Committee Chair / Thesis Advisor | |
| Committee Members |
Primary PDF
| Thumbnail | Title | Date Uploaded | Actions |
|---|---|---|---|
|
|
The Effect of Contingent Value Rights on Drug Approval in Biopharma M&A () | 2026-04-16 09:56:44 -0400 |
|
Supplemental Files
| Thumbnail | Title | Date Uploaded | Actions |
|---|